ModifiedCapital BluecrossPolicy MP 1.134

Tibial Nerve Stimulation

Medical policy governing percutaneous, subcutaneous (implantable), and transcutaneous tibial nerve stimulation for treatment of non-neurogenic and neurogenic urinary dysfunction and fecal incontinence for Capital BlueCross members.

Policy Summary

PayerCapital Bluecross

PolicyTibial Nerve Stimulation

Policy CodePolicy MP 1.134

Change TypeMaterial change — added investigational statement for transcutaneous TTNS and coding updates

Effective Date01/01/2026

Next Review DateN/A

Key ActionObtain prior authorization documenting failed behavioral (8–12 weeks) and pharmacologic (4–8 weeks) therapy before initiating an initial 12‑week PTNS course.

SourceLink

POLICY UPDATE CHANGES

Added new investigational (INV) statement for transcutaneous tibial nerve stimulation.

Title changed; formerly Percutaneous and Implantable Tibial Nerve Stimulation.

New procedure and investigational codes (0988T, 0989T) added to the investigational coding table effective 01/01/2026.

Administrative additions of codes A4545, E0736, E0737 and later moves of these codes into the investigational coding table.

12‑weekinitial PTNS course

4-8 wkpharmacologic trial

8-12 wkbehavioral trial

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

monthlymaintenance frequency

68%eCoin responder rate

new codesINV codes added

Coverage Criteria for Tibial Nerve Stimulation

inv-01: Initial PTNS (Percutaneous) — Medical Necessity

Covered when ALL of the following are met

Initial PTNS criteria: Individual has non-neurogenic urinary dysfunction (including overactive bladder, urinary frequency, urgency, or urge incontinence); AND Failed behavioral therapy after an appropriate duration of 8 to 12 weeks without meeting treatment goals; AND Failed pharmacologic therapy after 4 to 8 weeks of treatment without meeting treatment goals; AND Treatment is for indications cleared by FDA for PTNS (overactive bladder and associated symptoms); AND Initial course limited to 12 weekly office-based treatments.

Documentation of failed behavioral and pharmacologic therapies and treatment goals not met is required for prior authorization and medical necessity determination.

inv-02: Maintenance PTNS — Medical Necessity

Covered when ALL of the following are met

Maintenance PTNS criteria: Individual previously completed an initial 12-week course of percutaneous tibial nerve stimulation that resulted in improvement in urinary dysfunction meeting treatment goals; AND Maintenance therapy is delivered on an individualized schedule, typically approximately monthly (common regimens every 4-6 weeks); AND Annual physician evaluation may be performed to ensure ongoing efficacy of maintenance therapy.

Document prior 12-week course, demonstrated response, and ongoing benefit to support maintenance therapy and prior authorization.

inv-03: Subcutaneous (implantable) and Transcutaneous Tibial Nerve Stimulation — Not covered / investigational

Not covered / investigational

Investigational STNS/TTNS: Subcutaneous (implantable) tibial nerve stimulation (e.g., coin-sized leadless implantable systems such as eCoin) and transcutaneous tibial nerve stimulation (e.g., wearable or surface electrode systems such as the Vivally System) are considered investigational for all indications, including non-neurogenic overactive bladder and urge urinary incontinence, because evidence is insufficient to determine net health outcome.

Although certain implantable devices have FDA marketing letters/approvals (e.g., eCoin PMA), current evidence (single-arm studies, lack of comparator data, and variable study quality) is insufficient for payer coverage; see policy documentation for details.

inv-04: PTNS for Neurogenic Bladder and Fecal Incontinence — Not covered / investigational

Not covered / investigational

Neurogenic bladder and fecal incontinence: PTNS (including percutaneous, transcutaneous, or implantable approaches) is considered investigational for neurogenic bladder dysfunction and for fecal incontinence due to insufficient evidence of clinically meaningful benefit; randomized trials and systematic reviews have not demonstrated consistent superiority over sham or comparator treatments.

Available trials are heterogeneous, many used transcutaneous stimulation, and overall evidence is insufficient to determine effects on health outcomes.

inv-05: Coverage determinations by indication and device — Coverage stance varies by indication and device

Coverage stance varies by indication and device:

Implantable tibial nerve stimulators: Evidence from single-arm pivotal studies of implantable tibial nerve stimulators (e.g., eCoin) reported a 68% responder rate at 48 weeks versus a 40% performance goal, but limitations (no concurrent comparator, performance goal defined post-implantation, and concerns about battery lifespan and reimplantation) leave evidence insufficient to conclude a net health benefit.

Ongoing post-approval studies may provide additional data; see pivotal study and FDA PMA materials.

PTNS for neurogenic bladder: Several randomized trials and a systematic review exist but most trials used transcutaneous stimulation and were heterogeneous; study findings have not shown consistent reductions in incontinence symptoms or improved outcomes, so evidence is insufficient to support coverage for neurogenic bladder.

Trials varied in population and comparators; see evidence summary.

PTNS for fecal incontinence: Multiple randomized trials and systematic reviews for fecal incontinence have not demonstrated a clear benefit of PTNS over sham or comparators for primary outcomes; subgroup post-hoc analyses suggest possible benefit in select subsets but overall evidence is insufficient.

Per the policy, subcutaneous (implantable) tibial nerve stimulation (e.g., coin-sized leadless implants such as eCoin) and transcutaneous tibial nerve stimulation (e.g., wearable/surface electrode systems such as the Vivally System) are classified as investigational for all indications. The document states there is insufficient evidence to support a general conclusion about health outcomes or benefits for these technologies and therefore they are excluded from coverage.

The policy lists specific tibial nerve stimulation procedure and device codes as investigational and not covered. Examples cited include 0989T and related code groupings; the coding table in the policy identifies multiple investigational codes and notes administrative updates to the coding list.

Transcutaneous tibial nerve stimulation was added to the policy’s investigational (INV) statements during a recent minor review, and investigational services are excluded from coverage per the policy’s coding designations. The policy history documents this addition and subsequent moves of codes into the INV coding table.

The policy explicitly states that PTNS is considered investigational for indications other than the specified non-neurogenic urinary dysfunction. Examples of noncovered investigational indications include neurogenic bladder dysfunction and fecal incontinence, with the rationale that available randomized trials and systematic reviews do not demonstrate consistent, clinically meaningful benefits.

For several specific scenarios the policy takes an investigational stance: implantable tibial nerve stimulators (despite reported responder rates, limitations such as lack of a comparator group and post-hoc performance goals render evidence insufficient), PTNS for neurogenic bladder (most trials used transcutaneous stimulation with heterogeneous methods and no consistent benefit), and PTNS for fecal incontinence (sham-controlled trials and meta-analyses have not shown clear superiority). The policy notes clinical input supports maintenance PTNS after a documented response to an initial course for non-neurogenic OAB, but maintains investigational/not medically necessary determinations where comparative evidence is inadequate. The coding table also identifies investigational procedure codes associated with these technologies.

Codes placed in the policy’s investigational coding table are treated as investigational and therefore not medically covered. The policy history and coding section identify codes moved to or added in the INV table (for example, A4545, E0736, E0737, 0988T, and 0989T) and state that services billed with these codes may be denied as investigational per payer coding designations.

Coding and Regulatory Identifiers

Regulatory device 510(k)/PMA identifiers mentionedmixed

K052025	Urgent PC Neuromodulation System 510(k)
K061333	Urgent PC Neuromodulation System 510(k)
K071822	Urgent PC Neuromodulation System 510(k)
K101847	Urgent PC Neuromodulation System 510(k)
K132561	NURO Neuromodulation System 510(k)
K192731	ZIDA Wearable Neuromodulation System 510(k)
K220454	Vivally System Wearable Non-Invasive Neuromodulation 510(k)
P200036	eCoin PMA identifier

Investigational / Not Covered Procedure CodesCPTNot Covered

0989T	Listed among investigational tibial nerve stimulation device procedure codes
0588T	mapped to A4545 per document
0589T	mapped to E0736 per document
0590T	mapped to E0737 per document
0816T	listed in investigational codes section
0817T	listed in investigational codes section
0818T	listed in investigational codes section
0819T	listed in investigational codes section
0988T	listed in investigational codes section

Covered Procedure Codes (when medically necessary)CPTCovered

64566

Percutaneous tibial nerve stimulation; includes implantation of a peripheral neurostimulator lead, when performed

Relevant ICD-10 Diagnosis CodesICD-10

N32.81	Overactive bladder
N39.41	Urge incontinence
N39.42	Incontinence without sensory awareness
N39.43	Post-void dribbling
N39.44	Nocturnal enuresis
N39.45	Continuous leakage
N39.46	Mixed incontinence
N39.490	Overflow incontinence
N39.491	Coital incontinence
N39.492	Postural (urinary) incontinence

1–10 of 20

1/2

Codes added or moved per policy historymixed

0816T-0819T	Added to coding (administrative update)
E0736	Added to coding; later moved to investigational coding table
A4545	Added to coding; later moved to investigational coding table
E0737	Added to coding; later moved to investigational coding table
0988T	New code added to investigational coding table effective 01/01/2026
0989T	New code added to investigational coding table effective 01/01/2026

Regulatory identifiersmixed

P200036

FDA PMA identifier for eCoin® Peripheral Neurostimulator

Behavioral therapy duration — 8-12 weeks

Required durationBehavioral therapy should be tried for 8–12 weeks before PTNS is considered; failure is defined as not meeting treatment goals after this period.

DocumentationClinical record must document start and end dates and outcomes of the 8–12 week behavioral therapy trial.

ContextBehavioral therapy is part of required conservative management for non-neurogenic urinary dysfunction including OAB prior to PTNS.

Pharmacologic therapy duration — 4-8 weeks

Required durationPharmacologic therapy should be tried for 4–8 weeks before PTNS is considered; failure is defined as not meeting treatment goals after this period.

Prior Authorization, Documentation, and Billing Actions

Prior Authorization

Prior Authorization Required and Coverage Guidance

Prior authorization is required. Requests must document failure of conservative therapies (behavioral therapy for 8–12 weeks and pharmacologic therapy for 4–8 weeks) before initial percutaneous tibial nerve stimulation (PTNS). Coding identification in this policy does not guarantee coverage; member-specific benefit terms apply.

Prior authorization required before initial PTNS
Document behavioral therapy duration (8–12 weeks) and pharmacologic therapy duration (4–8 weeks) and that treatment goals were not met
Coverage determined by member benefit information; coding list may not be all-inclusive

Billing Rule

Code-level Coverage and Prior Authorization

Background and Evidence Summary

Overactive bladder (OAB) is a non-neurogenic voiding dysfunction characterized by urinary frequency, urgency, urge incontinence, and nonobstructive retention. Percutaneous tibial nerve stimulation (PTNS) modulates the posterior tibial nerve to retrogradely stimulate lumbosacral nerves (L4–S3) to improve bladder control. PTNS is less invasive than sacral neuromodulation and is typically delivered as an initial course of 12 weekly office-based treatments followed by individualized maintenance (often approximately monthly).

Definitions and Device Descriptions

Overactive bladder (OAB) definition

DefinitionOveractive bladder (OAB) is a non‑neurogenic voiding dysfunction characterized by urinary frequency, urinary urgency, urge incontinence, and nonobstructive retention.

ScopeOAB is the FDA‑cleared indication for percutaneous tibial nerve stimulation (PTNS).

Clinical relevanceOAB diagnosis is a required indication for coverage of initial PTNS when conservative therapy has failed.

Percutaneous tibial nerve stimulation (PTNS) — procedure description

Procedure descriptionPercutaneous tibial nerve stimulation (PTNS) involves inserting a needle above the medial malleolus to apply low‑voltage (≈10 mA, 1–10 Hz) electrical stimulation to the posterior tibial nerve, producing sensory (tickling) and motor (plantarflexion/fanning of toes) responses.

Treatment course

Policy Revision History

2025-05-16Minor Review

Title changed (formerly 'Percutaneous and Implantable Tibial Nerve Stimulation') and a new investigational statement was added for transcutaneous tibial nerve stimulation; A4545, E0736, and E0737 were moved to the investigational coding table.

2025-09-10Administrative Update

Removed Benefit Variations section and updated Disclaimer.

2025-12-11Administrative UpdateLatest

Policy Summary

PayerCapital Bluecross

PolicyTibial Nerve Stimulation

Policy CodePolicy MP 1.134

Change TypeMaterial change — added investigational statement for transcutaneous TTNS and coding updates

Effective Date01/01/2026

Next Review DateN/A

Key ActionObtain prior authorization documenting failed behavioral (8–12 weeks) and pharmacologic (4–8 weeks) therapy before initiating an initial 12‑week PTNS course.

SourceLink

On This Page

Larger sham-controlled trials and meta-analyses do not support consistent benefit.

Transcutaneous tibial nerve stimulation for urge urinary incontinence/urgency: Randomized and nonrandomized studies of transcutaneous tibial nerve stimulation show mixed results: one RCT reported improvement on a composite patient-reported primary outcome but no differences in individual symptom measures; nonrandomized studies report improvements but lack reporting of minimal clinically important differences; evidence is insufficient to demonstrate net health benefit.

Heterogeneity in outcomes and study designs limit definitive conclusions.

Maintenance PTNS for non-neurogenic OAB: Clinical input supports use of maintenance PTNS for individuals with non-neurogenic urinary dysfunction (including OAB) who have failed behavioral and pharmacologic therapies and who responded to an initial 12-week course; maintenance therapy may provide clinically meaningful improvement and is consistent with accepted practice.

Supported by clinical input from physician respondents; typical maintenance intervals every 4-6 weeks though individualized.

DocumentationClinical record must document medication(s) used, dosing, duration (4–8 weeks), and response or intolerance.

ContextPharmacologic therapy is required after behavioral therapy failure and prior to initiating PTNS for non-neurogenic urinary dysfunction.

Initial PTNS course — 12 weekly treatments

Initial courseInitial PTNS consists of a series of 12 weekly office-based treatments.

AdministrationNeedle insertion above the medial malleolus with low-voltage electrical stimulation producing sensory/motor responses; recommended as weekly sessions.

Maintenance noteAn initial 12-week course is required for consideration of maintenance PTNS; maintenance frequency is individualized (typical every 4–6 weeks).

Some tibial nerve stimulation procedure codes are placed in the investigational coding table and may affect prior authorization handling. CPT code 64566 is listed as covered when medically necessary for PTNS; other listed or new investigational codes may be denied as not covered.

64566 — covered when medically necessary for percutaneous tibial nerve stimulation
Investigational coding table includes newer procedure codes; services billed with investigational (INV) codes may be denied

Denial Risk

Investigational Codes and Prior Authorization

Codes associated with newer or investigational tibial nerve stimulation technologies have been added to the investigational (INV) coding table. Providers should expect that procedures billed with these investigational codes could be reviewed and denied; submit appropriate documentation with prior authorization requests.

INV coding table updated over time (see policy history)
Providers should include clinical documentation when requesting prior authorization for codes that may be investigational

Documentation Required

Failure of Conservative Therapy Required

Requests for PTNS without documented failure of conservative therapy (behavioral therapy for 8–12 weeks and pharmacologic therapy for 4–8 weeks) may be denied. Documentation should state duration, specific therapies tried, outcomes, and that treatment goals were not met.

Behavioral therapy: 8–12 weeks with documentation of outcomes
Pharmacologic therapy: 4–8 weeks with documentation of outcomes
Failure of conservative therapy must be clearly documented or request may be denied

Denial Risk

Investigational Tibial Nerve Stimulation Technologies

Subcutaneous (implantable) tibial nerve stimulation (e.g., eCoin®) and transcutaneous tibial nerve stimulation (e.g., Vivally System) are considered investigational for all indications in this policy and are not covered.

Subcutaneous/implantable tibial nerve stimulation (e.g., eCoin®) — investigational, not covered
Transcutaneous tibial nerve stimulation (e.g., Vivally System) — investigational, not covered

Denial Risk

Investigational Devices Not Covered

The policy lists specific tibial nerve stimulation devices and associated procedure codes considered investigational and therefore not covered; providers should not assume coverage for listed investigational device codes.

Several procedure codes (including newly added 0816T–0819T, A4545, E0736, E0737, 0988T, 0989T) are placed in the investigational coding table and are not covered
Identification of a code in coding section does not denote coverage; verify member-specific coverage

Documentation Required

Coding and Documentation Note

When submitting prior authorization requests, include coding and clinical documentation that supports medical necessity. The coding list in this policy may not be exhaustive and code assignment does not equal coverage — submit all supporting notes, prior therapy durations, and response to therapy.

Include clinical notes documenting therapy durations and outcomes
Submit rationale for medical necessity when using codes that may appear investigational

Documentation Required

Coding Documentation and Policy History

Policy history documents changes to the coding table distinguishing medically necessary versus investigational codes. Providers should submit appropriate documentation with authorization requests and be aware that codes moved to the investigational table (per policy history) may result in noncoverage.

Policy history documents additions and moves of codes (e.g., A4545, E0736, E0737 moved to INV; 0988T/0989T added)
Providers should reference policy history when reconciling coding coverage and include supporting documentation with prior auth requests

Step Therapy

Step Therapy Sequence

Step-therapy expectations: behavioral therapies (including pelvic floor exercises, bladder training, lifestyle modification) and pharmacotherapy should be tried and documented as failed before initiating PTNS. No additional explicit step-therapy sequencing beyond these requirements is stated.

Behavioral management (pelvic floor exercises, bladder training, lifestyle changes) — try for 8–12 weeks
Pharmacotherapy — try for 4–8 weeks
No other explicit step-therapy sequence required beyond documentation of these failures

Note

Maintenance PTNS After Successful Initial Therapy

Clinical input supports maintenance PTNS (monthly) for individuals with non-neurogenic urinary dysfunction who responded to an initial 12-week PTNS course after failing behavioral and pharmacologic therapies. Annual physician evaluation may be performed to ensure continued efficacy.

Maintenance monthly PTNS considered medically necessary after successful initial 12-week course that met treatment goals
Annual physician evaluation recommended to assess ongoing efficacy for maintenance PTNS

Recommended initial series is 12 weekly office‑based treatments followed by individualized maintenance.

MechanismPTNS is believed to retrogradely stimulate lumbosacral nerves (L4–S3) to improve bladder control.

Subcutaneous tibial nerve stimulation (STNS) — implantable device description

Device descriptionSubcutaneous tibial nerve stimulation (STNS) uses a coin‑sized, leadless, battery‑powered implantable device (e.g., eCoin®) that delivers automated subcutaneous stimulation to the tibial nerve.

Regulatory noteeCoin® received FDA PMA (see PMA P200036) for urgency urinary incontinence; pivotal evidence from an open‑label single‑arm trial is cited.

Coverage stanceDespite FDA approval, STNS (implantable devices) is considered investigational by the payer for all indications due to insufficient evidence of net health benefit.

Transcutaneous tibial nerve stimulation (TTNS) — wearable/surface electrode description

Device descriptionTranscutaneous tibial nerve stimulation (TTNS) uses a wearable stimulator and surface electrodes (often worn on the ankle) to deliver electrical signals to the tibial nerve; typically an at‑home treatment.

Example deviceVivally System is an FDA‑cleared transcutaneous system for urge urinary incontinence and urinary urgency.

AdministrationDelivered noninvasively via surface electrodes rather than percutaneous needle placement.

Urge incontinence definition

DefinitionUrge incontinence: leakage of urine when there is a strong urge to void.

Clinical implicationUrge incontinence is a key symptom of overactive bladder and a target symptom for PTNS therapy.

DocumentationAssessment of urge incontinence should be included in clinical records when evaluating response to conservative therapy and PTNS.

Urgency-frequency definition

DefinitionUrgency‑frequency: an uncontrollable urge to urinate resulting in very frequent, small volumes.

Relation to OABUrgency‑frequency is a common manifestation of overactive bladder considered when determining treatment eligibility.

AssessmentDocument frequency and volume patterns during conservative therapy trials and PTNS evaluation.

Urinary retention definition

DefinitionUrinary retention: the inability to completely empty the bladder of urine.

DistinctionRetention may be neurogenic or nonobstructive; nonobstructive retention is listed among OAB‑related symptoms.

Clinical noteUrinary retention is part of the differential diagnosis when evaluating voiding dysfunction prior to PTNS.

eCoin® — device entry and PMA reference

Device entryeCoin® is a leadless peripheral tibial nerve neurostimulator documented in the FDA PMA database (PMA P200036).

Evidence citationPivotal open‑label, single‑arm trial of eCoin® for urgency urinary incontinence is cited (Rogers et al., J Urol. 2021).

Payer stanceAlthough FDA‑approved, implantable devices such as eCoin® are considered investigational by the payer for all indications due to insufficient evidence of net health benefit.

Added new investigational codes 0988T and 0989T to the investigational coding table effective 2026-01-01.